About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Journal of Caffeine Research

Editor-in-Chief: Patricia A. Broderick, PhD

ISSN: 2156-5783 • Published Quarterly • Online ISSN: 2156-5368

Current Volume: 4

Call for Papers: Special Issue on Caffeine and Depressive Disorders

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science is a peer-reviewed journal dedicated exclusively to the study of caffeine. The Journal publishes original studies, review articles, commentary, discussion, and debate. It is multidisciplinary in scope, covering basic, applied, clinical, experimental, translational, and observational approaches in the biomedical, behavioral, social, epidemiological, and clinical sciences. It covers all aspects of caffeine science and is concerned with all stages of the human life span from prenatal exposure to end-of-life. The Journal does not publish articles that have been submitted or published elsewhere.

    Manuscripts must be submitted online using the following URL http://mc.manuscriptcentral.com/caffeine


    Please read all the instructions to authors before submitting. 


    Please read all the instructions to authors before submitting.

    Be prepared to enter:

    • The title of the article.
    • You will be asked to enter the full names and institutional affiliations of all authors, the name (with complete address, phone and fax numbers, and e-mail address) to whom correspondence should be directed.
    • A running title of no more than 45 characters (including spaces).
    • Provide a structured Abstract of no more than 250 words, stating the background, methods, results (including the sample size), and conclusions drawn from the study.
    • You will be asked to enter 3–5 keywords or phrases.

    You will also be asked for the names and e-mail addresses of at least five potential preferred reviewers familiar with the field.  Please make sure preferred reviewers are not from your university or institution with whom you have collaborated.  Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer.

    The author will also be asked to confirm that the material has not been published or submitted for publication elsewhere. All material published in the Journal will be copyrighted by Mary Ann Liebert, Inc. 


    All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.


    All manuscripts must be prepared in accordance with the "Uniform Requirements for Manuscripts Submitted for Biomedical Journals." Prepare text in double-spaced format  in Microsoft Word. Leave ample margins on the sides, top, and bottom of pages. The order of items in the manuscript is: title page, abstract, text, acknowledgment(s), disclosure(s), references, reprint address, legends, and tables. Each page, including the title page, must be numbered in the upper right-hand corner. Number pages consecutively.
    Text.  Maximum word count should not exceed 4000 words.  In General, the text should be organized under the headings: Introduction, Materials and Methods, Results, Discussion, and Conclusions. Use only standard abbreviations, which can be found in the AMA’s Manual for Authors & Editors or the Council of Biology Editors Style Manual.  At first usage, spell out terms and give abbreviations in parentheses. Thereafter, use only abbreviations. It is not necessary to spell out standard units of measure, even at first usage. Use generic names for drugs if possible. If you wish to use a proprietary drug name the first time it appears, use the generic name followed by the proprietary name and manufacturer in parentheses.
    .  The author should acknowledge only those people and their institutions that have made significant contributions to the study.
    Disclosure Statement
    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the manuscript, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscript. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at www.icmje.org/index.htlm#conflicts for further guidance. If no conflicts exist, all authors must state “No competing financial interests exist."


    Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper.  Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.

    References.  References must be prepared double spaced and numbered consecutively as they are cited in the text (using superscript numbers in text). References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by MEDLINE, National Library of Medicine. List all authors when there are six or less. When there are more than six, list the first three, followed by et al. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (F. P. Haseltine, personal communication). Include, among the references, papers accepted but not yet published; designate the journal, and add "In Press."  
    Sample references are:
    Journal article
    Morelli M, Simola  N. Can dietary substances protect against Parkinson's disease? The case of caffeine.  Exp Neurol. 2010;225:246-249.
     Higdon J. An Evidence-Based Approach to Dietary Phytochemicals. Germany: Thieme Georg Verlag; 2006.
    Chapter in an Edited Book:
    Myers JP, Johnson DA, McVey DD. Caffiene in the modulation of brain function. In: Caffeine and Behavior: Current Views and Research Trends. B.S. Gupta and Uma Gupta (Eds). Boca Raton, FL: CRC Press; 1999: pp. 17-30.
    Reprint Address.  Following the references, provide the name and complete address of the person to whom reprint requests should be sent.

    Tables.  Prepare tables double spaced, each as a separate file, and provide a title for each table. Cite tables in sequence in the text. Define abbreviations used in the body of the table in table footnotes. If a table is taken from a copyrighted publication, credit must be given in a footnote.   
    Figures.  Cite figures consecutively in the manuscript within parentheses: A legend should be supplied for each illustration, and all legends numbered consecutively and provided (double spaced).  Figures should be numbered in the order cited in the text. Images should not show the name of the manufacturer. 
    When naming your figure files, please label them with the corresponding author’s last name, followed by a period (.), and then list the figure number.  Ex:  Jones.Fig1.  
    Electronic submission of art follows these caveats:
    •          Do not include any illustrations as part of your text file.
    •          Do not prepare any figures in Word as they are not workable.
    •          Line illustrations must be submitted at 900 DPI.
    •          Halftones and color photos should be submitted at a minimum of 300 DPI.
    •          Adobe is the preferred software.  Do NOT submit PowerPoint files.
    •          Save art as either TIFF or EPS files.  Avoid submitting JPEG files.
    •          Color art must be saved as CYMK not RGB.

    Legends.  You may enter the legends for each image as you upload each individual file, or you may upload a separate file for legends. Each legend for illustrations must be double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. on the art work. If the illustration is taken from a copyrighted publication, permission must be procured by the authors, and credit must be given in the legend.  A full citation for the credited work should be provided in the reference section as a numbered reference.


    The author(s) must secure written permission for any reprinted material. Materials taken from other sources must be accompanied by a written statement from the copyright holder (usually the publisher) giving permission to  Journal of Caffeine Research for reproduction. If clearance is required by the author’s institution, statements concerning such clearance should be provided in the manuscript. Obtain and submit written permission from authors to cite unpublished data or papers still in press.  


    An e-mail containing a link to the PDF file of the page proof is sent to the corresponding author. The proof should be read carefully and returned promptly to the Publisher with the author’s approval and/or corrections.


    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.



    The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; Fax: (914) 740–2101; E-mail: info@liebertpub.com;  Website: www.liebertpub.com

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy

    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 




The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.